Preprint Review Version 1 Preserved in Portico This version is not peer-reviewed

Antithrombotic Therapy in Patients Undergoing Transcatheter Aortic Valve Implantation

Francesco Pallante
,
Francesco Costa
* ,
Victoria Garcia Ruiz
,
Giampiero Vizzari
,
Pietro Iannello
,
Lucio Teresi
,
Gabriele Carciotto
ORCID logo ,
Stefania Lo Giudice
,
Giustina Iuvara
,
Giulia Laterra
,
Ander Regueiro
ORCID logo ,
Gennaro Giustino
,
Juan Horacio Alonso Briales
,
Jose Maria Hernandez
,
Marco Barbanti
,
Antonio Micari
,
Francesco Patanè
Version 1 : Received: 20 May 2024 / Approved: 21 May 2024 / Online: 21 May 2024 (14:02:21 CEST)

How to cite: Pallante, F.; Costa, F.; Garcia Ruiz, V.; Vizzari, G.; Iannello, P.; Teresi, L.; Carciotto, G.; Lo Giudice, S.; Iuvara, G.; Laterra, G.; Regueiro, A.; Giustino, G.; Alonso Briales, J. H.; Hernandez, J. M.; Barbanti, M.; Micari, A.; Patanè, F. Antithrombotic Therapy in Patients Undergoing Transcatheter Aortic Valve Implantation. Preprints 2024, 2024051401. https://doi.org/10.20944/preprints202405.1401.v1 Pallante, F.; Costa, F.; Garcia Ruiz, V.; Vizzari, G.; Iannello, P.; Teresi, L.; Carciotto, G.; Lo Giudice, S.; Iuvara, G.; Laterra, G.; Regueiro, A.; Giustino, G.; Alonso Briales, J. H.; Hernandez, J. M.; Barbanti, M.; Micari, A.; Patanè, F. Antithrombotic Therapy in Patients Undergoing Transcatheter Aortic Valve Implantation. Preprints 2024, 2024051401. https://doi.org/10.20944/preprints202405.1401.v1

Abstract

Transcatheter Aortic Valve Implantation (TAVI) now represents the mainstay in the treatment of severe aortic stenosis. Owing to its exceptional procedural efficacy and safety, TAVI has been extended to include patients at lower surgical risk, thus now encompassing a diverse patient population receiving this treatment. Yet, long-term outcomes also depend on optimal medical therapy for secondary vascular prevention, with antithrombotic therapy serving as a cornerstone. Leveraging data from multiple randomized controlled trials, current guidelines generally recommend single antithrombotic therapy, with either single antiplatelet therapy (SAPT) or oral anticoagulation (OAC) alone in those patients without, or with atrial fibrillation respectively. Yet, individualization of this pattern, as well as specific case uses, may be needed based on individual-patient characteristics and concurrent procedures. This review aims to discuss the evidence supporting antithrombotic treatments in patients treated with TAVI, indications for a standardized treatment, as well as specific considerations for an individualized approach to treatment.

Keywords

Antithrombotic therapy; Aortic valve stenosis; Transcatheter Aortic Valve Implantation (TAVI); Transcatheter Aortic Valve Replacement (TAVR); bleeding risk; thrombotic risk; tailored therapy; risk scores.

Subject

Medicine and Pharmacology, Cardiac and Cardiovascular Systems

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Download PDF

Comments (0)

We encourage comments and feedback from a broad range of readers. See criteria for comments and our Diversity statement.

Leave a public comment
Send a private comment to the author(s)
* All users must log in before leaving a comment
Views 0
Downloads 0
Comments 0
Metrics 0
Get PDF Cite Share 0
Bookmark BibSonomy Mendeley Reddit Delicious
×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.